Laverock Therapeutics bags additional £6.5m seed money

Laverock Therapeutics has expanded its seed funding to a total of £20m through an extension of approximately £6.5m. This second investment round after a seed round in 2023 was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and Maven Capital Partners. The company also welcomed new investor, Norcliffe Capital.

The company, which in a transition to lead product selection, will use the additional funds to optimise its preclinical   primary T-cell and macrophage-based programmes LKV201 and LKV301 to fight haematological and solid tumours. Laverock platform technology to enhance  efficacy, precision and safety of advanced therapies.

The company firstly selects non-coding miRNAs with desired expression patterns, modifies them using gene editing to identify highly selective mRNA expression blockers. This results in programmable control over gene expression, linking gene silencing to specific cell identities and states.

David Venables, CEO of Laverock, said that the new funding will be used to advance Laverock’s early-stage pipeline and to form partnerships and collaborations to integrate the company’s pltform and know-how into partners’ therapeutic pipelines.